RIGEL PHARMACEUTICALS INC
RIGLOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M | $108.6M |
| Operating income | $125.5M | $24.2M | −$20.5M | −$55.5M | −$12.5M | −$29.0M |
| Net income | $367.0M | $17.5M | −$25.1M | −$58.6M | −$17.9M | −$29.7M |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M | $110.4M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M | — |
| Equity | $391.5M | $3.3M | −$28.6M | −$13.6M | $30.4M | $34.0M |
| EPS (diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 | $-0.18 |
| Shares out. | 17.9M | 175.4M | 173.7M | 171.7M | 170.0M | 168.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 42.6%
- Net margin
- 124.7%
- Return on equity
- 93.8%
- Return on assets
- 71.5%
- Return on capital (ROCE)
- 30.3%
- Liabilities / assets
- 23.8%
- Debt / equity
- 0.31×
- Book value / share
- $21.92
- Revenue growth (YoY)
- 64.1%
- Net income growth (YoY)
- 1999.1%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 0.31distress
- Accruals / assets
- 56.7%high accruals
- Beneish M-Score
- 1.63elevated
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 2 warning● 5 good- Altman Z″ in the distress zone
- High accruals — earnings-quality risk
- Beneish M-Score elevated — earnings-manipulation screen flag
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ali-Jackson KamilDirector | May 26, 2026 | Sell | 2,500 | $29.17 |
| Wasman JaneDirector | May 15, 2026 | Grant | 5,750 | $0.00 |
| Moos Walter HDirector | May 15, 2026 | Grant | 5,750 | $0.00 |
| Miller Michael PatrickDirector | May 15, 2026 | Grant | 5,750 | $0.00 |
| Lapointe Anthony GreggDirector | May 15, 2026 | Grant | 5,750 | $0.00 |
| Hannah Alison L.Director | May 15, 2026 | Grant | 5,750 | $0.00 |
| Frohlich Mark WDirector | May 15, 2026 | Grant | 5,750 | $0.00 |
| Ali-Jackson KamilDirector | May 15, 2026 | Grant | 5,750 | $0.00 |
| Moos Walter HDirector | Feb 20, 2026 | Option exercise | 4,000 | $24.00 |
| Furey Raymond J.Officer — EVP, GC, CCO & Corp Sec | Feb 17, 2026 | Grant | 19,497 | $0.00 |
| Rodriguez Raul ROfficer — CEO, President | Feb 17, 2026 | Grant | 53,915 | $0.00 |
| Rojkjaer LisaOfficer — EVP, Chief Medical Officer | Feb 17, 2026 | Grant | 18,894 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.9M | 7.5 | +0.3% |
| Apr 30, 2026 | 3.9M | 12.1 | -4.5% |
| Apr 15, 2026 | 4.1M | 11.3 | +8.2% |
| Mar 31, 2026 | 3.8M | 13.3 | +2.2% |
| Mar 13, 2026 | 3.7M | 7.1 | -0.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 20, 2026
- Entered a material agreementMay 12, 2026
- Results of operationsMay 5, 2026
- Terminated a material agreementApr 21, 2026
- Results of operationsMar 3, 2026
- Director / officer changeFeb 3, 2026
- Results of operations · Other material eventJan 12, 2026
- Other material eventDec 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.